Newsletter · 2026-08-14 · Ashutosh Agarwal

Lilly's Record Quarter and a Rumored $400 Billion AstraZeneca Merger Rock Pharma - Healthcare Podcast Weekly Digest - Week of August 14, 2026

Podcast coverage of Eli Lilly's record quarter, a rumored $400 billion AstraZeneca and Bristol-Myers merger, a biotech dealmaking wave, and an unpredictable FDA, for the week of August 8 to 14, 2026.

Healthcare Podcast Weekly Digest

Week of August 8–14, 2026: Lilly's Record Quarter and a Rumored $400 Billion AstraZeneca Merger Rock Pharma

What the podcasts were talking about this week in pharma, biotech, medical devices, hospitals, and health insurance, with the numbers, the names, and why it matters.

1. The Week in a Nutshell

This was the busiest healthcare week of the summer, and one theme sat on top of everything: Eli Lilly. The company reported roughly $23 billion of revenue in a single quarter, up 48% from a year earlier, almost all of it powered by its weight-loss and diabetes drugs, and it used the moment to remind everyone just how far ahead it is of its only real rival, Novo Nordisk.

But the bigger jolt came before earnings even started. Over the weekend, the Financial Times reported that two giants, the UK's AstraZeneca and America's Bristol-Myers Squibb, had been quietly talking about a merger that would create a roughly $400 billion company, the largest drugmaker of all time. Neither side confirmed it, analysts think it probably won't happen, and yet it dominated every investing podcast because of what it says about where the whole industry is heading.

Underneath those two stories, three currents ran through the week's podcasts:

• A wave of dealmaking. One podcast counted $18 billion of biotech changing hands in 72 hours. Vertex is buying, Lantheus is being bought, BioNTech is shrinking, and hospital systems are reshuffling too.
• The regulators are unpredictable again. A twice-rejected melanoma drug finally got approved. A muscular-dystrophy therapy got voted down. And Washington is rewriting the rules on Medicaid and drug pricing in ways that squeeze hospitals.
• A quiet defensive rotation into healthcare. With money leaving expensive tech, several podcasts noted investors drifting toward steady, dividend-paying healthcare names, even as the mega-cap drug and insurance stocks each carry their own headaches.

2. Key People This Week

3. Hot Topics: the names everyone talked about

Eli Lilly ($LLY): "printing money," and spending it just as fast

The numbers, laid out across BioSpace, the Elon Musk Podcast, and On The Pen this week:

• Revenue ~$23 billion, +48% year-over-year. Net income rose about $1.5 billion to $7.1 billion. Adjusted earnings were $8.38 a share, up 33% (Lilly Q2 report, Aug 5).
• The two workhorses: Mounjaro (diabetes) jumped 91% to about $9.9 billion, and Zepbound (weight loss) brought in $4.93 billion. Together they're roughly 65% of all of Lilly's revenue, spectacular, but also, as the Elon Musk Podcast put it, "a structurally vulnerable position," because two-thirds of an $87 billion company now rests on two products.
• Lilly raised its full-year revenue guidance to $85–87 billion (from $82–85B). Its market value has crossed $1 trillion.

The most interesting tension is between soaring volume and falling prices. As the Elon Musk Podcast explained: worldwide volume surged 60%, but the average realized price dropped 13%, down 3% in the US (from cutting Zepbound's cash price to reach uninsured patients) and a startling 36% internationally, largely because Mounjaro joined China's national reimbursement list. The trade is deliberate: give up price to buy access to a billion-person market.

And Lilly is plowing the cash straight back in: $4.5 billion to expand manufacturing in Indiana, plus a $2.78-per-share charge for acquiring early-stage biotech science (Orna, Ajax, Sintessa, and others). That charge, which was just $154 million the year before, essentially wiped out Lilly's underlying earnings growth for the quarter. CEO David Ricks is, in the podcast's words, "willing to sacrifice short-term margins" to "choke out future competitors who just can't match the production scale."

The pipeline prize is retatrutide, a next-generation "triple-agonist" that hits three targets instead of two, and in On The Pen's words is "the king of the hill when it comes to clinical trial data so far." More on the regulatory fight over it below. As On The Pen summed up the strategy: "The way that you see Lilly with obesity today is how you'll see them with oncology in the future… autoimmune disorders in the future."

One genuine miss: Lilly's new oral GLP-1 pill, Foundayo/Fondeo (orforglipron), took in only about $98 million in its first quarter, versus $355 million for Novo Nordisk's oral Wegovy in its first quarter earlier this year. BioSpace explained why: Novo could tell patients "here's Wegovi, you know it, switch to the pill," while Lilly is marketing a brand-new molecule from scratch. Interestingly, On The Pen noted that even on Medicare's new $50/month "Bridge" program, ~80% of patients are still choosing injectables over pills, because they're more potent, and "people with obesity are looking for the best bang for the buck."

Novo Nordisk ($NVO): the other side of the duopoly

The contrast was stark. On The Real Eisman Playbook, Steve Eisman put it bluntly: Lilly's EPS was $8.38, up 33%; Novo's was $4.75, down 20%, "and there is no indication" its new GLP-1 pill "is closing the gap." Reporting this week added the rest of Novo's rough quarter: sales of roughly DKK 78.5 billion ($12.1 billion), shares down about 6% even after raising guidance, a DKK 6.3 billion writedown on a pipeline asset, a failed late-stage trial for ziltivekimab, and a head-to-head study (REDEFINE-4) where Novo's Kagrisema delivered 23.0% weight loss versus tirzepatide's 25.5%. Lilly now holds roughly 60% of the US GLP-1 market.

UnitedHealth and the insurers: "not what insurance companies are anymore"

The sharpest single stock discussion of the week came from Dr. Bradley Gibson on the Chip Stock Investor Podcast, dissecting how UnitedHealth ($UNH) stopped being a plain insurer:

• It owns one of the largest pharmacy-benefit managers (PBMs), Optum, the middleman that negotiates drug prices and collects hidden manufacturer rebates.
• It owns a data network so large that when its Change Healthcare unit was hacked, "about 40% of the medical charges in America" couldn't flow through, while United kept collecting premiums.
• It directly employs about 90,000 doctors, just under 10% of the entire US physician workforce.

Gibson's warning: when United tried "pay-for-value" (a fixed budget per member) in 2025 and got the math wrong, it swung from making $7 billion to losing nearly $1 billion as patients used more care than expected. He framed a broader worry, hospitals consolidating, small practices dying, insurers vertically integrating, as "a healthcare bubble," asking, "when the healthcare bubble bursts, what's on the other side of that?"

Context from reporting this week: managed-care earnings were actually strong (health-care providers and services grew Q2 earnings ~30% year-over-year), but employers are staring at health-premium increases of 10% or more at renewal. Elevance Health ($ELV), the insurer formerly known as Anthem, was singled out as a relative value at roughly 12x forward earnings.

The GLP-1 cost bomb landing on employers

Several podcasts zeroed in on who actually pays for the weight-loss boom, the employers. On Morning Brew Daily, the eye-popping figure was Bank of America spending ~$250 million a year on GLP-1s for its 211,000 employees, 13% of its $2 billion health budget. But BofA is the exception: only about one-third of employers cover these drugs, PwC has dropped weight-loss coverage, and adding GLP-1 coverage can push everyone's premiums up ~10.4%, creating, as the hosts noted, real "inter-office tension."

Broken Benefits gave the ground-level view from CHRO Paul Dumas, whose health costs jumped 19.5% last year:

"In January, we were looking at a $15 million increase to budget that was not planned for… The driving force of this was the GLP-1s."

His deeper discovery was about the plumbing: manufacturers, he said, charge "$1,200 for a drug that we now know costs $199," while PBMs and brokers collect rebates and commissions that keep the price high. His fix, fire the broker, move to a transparent PBM, and drive rebates to zero, leads directly into this week's biggest emerging theme (Section 5).

4. Key Debates: the arguments cutting both ways

Will AstraZeneca actually buy Bristol-Myers Squibb?

This was the debate of the week, dissected on BioSpace, Investors' Chronicle, Health:Further, and even a listener call on InvestTalk.

The bull case (why it could make sense):

• It would create "the deepest bench in oncology in the world" (BioSpace), combining AstraZeneca's solid-tumor strength with BMS's hematology and cell-therapy franchises.
• It hands AstraZeneca a bigger US footprint: BMS earns ~70% of revenue in the US versus AstraZeneca's ~42% (Investors' Chronicle).
• AstraZeneca has a target of $80 billion in sales by 2030 and needs even more (~$100B) to fund its research. As Investors' Chronicle noted, it hit its last big target only by buying Alexion in 2023, so M&A may be how it gets there again.
• If it works, it could "reset the entire biopharma deal environment," mega-deals begetting more mega-deals (BioSpace).

The bear case (why it probably won't happen):

• Antitrust. The two overlap in cancer immunotherapy; UBS is already modeling forced divestitures (Investors' Chronicle).
• BMS's patent cliffs. Its blockbusters Eliquis and Opdivo, together ~$48 billion, about half of 2025 sales, face 2028 generics. William Blair warned bolt-on deals "may prove difficult to offset the decline of legacy products."
• Dilution and politics. AstraZeneca is roughly double BMS's size, so it's really an acquisition dressed as a merger; investors already knocked ~7% off AstraZeneca. And a UK company swallowing a marquee US drugmaker "could be awkward at a time when US policymaking seems to be about defending home industry" (Investors' Chronicle).

The tell: neither company denied the report, which most hosts read as confirmation the talks are real, even if a deal never lands.

Vertex vs. BioNTech: buy the future, or admit you don't have one?

Telltales framed the week's biotech tape as "three companies making three incompatible bets on the same decade":

• Vertex ($VRTX) is buying, paying $10 billion cash for Krenetics, "a pipeline it can't sell for years," funded by a franchise strong enough to raise guidance the same week.
• Lantheus is being bought by Curium.
• BioNTech ($BNTX) is shrinking, cutting guidance, closing plants, and buying back stock at just ~7x cash flow, which the host called "the most honest of the three… a market that has stopped underwriting a future at all."

The provocative takeaway: with a private buyer (Curium) and a strategic buyer (Vertex) both paying above where public markets had these assets valued, "the listed multiple stops being the opinion that matters."

Is the FDA predictable again?

After a year of turbulence under former Commissioner Marty Makary (who has since left), the Biotech Hangout and BioSpace crews debated whether approvals are back to normal, and concluded: not really.

• Replimune's melanoma drug (now named Tudrykev) was approved after being rejected twice, on a 10–3 advisory vote, even though the FDA itself called the data package "not interpretable."
• Capricor's Duchenne muscular dystrophy therapy was voted down.
• Miriam Fertility's liver-disease drug Volixabat got asked for a whole new Phase 3 trial despite strong data, which Biotech Hangout called "a signal of a really conservative decision," especially since the FDA approved a weaker GSK competitor months earlier.

As one host put it: "The unexpected continues to be expected these days."

5. Emerging Themes

1. Cutting out the middleman: direct-to-employer drugs. The freshest idea this week, from Jay Bregman of Andel on Off the Chart. His company buys brand drugs like Zepbound straight from the manufacturer and sells to employers with no PBM, no prior authorization, no rebates: patients pay "as little as $100 per fill" and get the drug shipped the next day, with nothing changing for their doctor. GLP-1s are the wedge because their demand "broke the traditional model for coverage." Both Lilly and Novo have opened their own direct channels, and, echoing Paul Dumas on Broken Benefits, the underlying question is getting louder: "Why do you even need the PBM?"

2. Pharma is consolidating, and AI is the accelerant. The through-line from Health:Further: "We're in a consolidation and M&A environment in pharma and biotech speeding up because of AI." The logic, patent cliffs plus the rising cost of pipelines (borrowing costs for pharma now top 9%, per Investors' Chronicle), is pushing the big "commercialization houses" to bulk up so they have the balance sheet to keep buying assets.

3. "Buying the decade." As Telltales observed, "the biggest checks anyone wrote were for assets that don't pay off until the 2030s." A good quarter got you nothing this week; investors are paying for the next five years.

4. The uninsured are starting to hit hospitals. Health:Further flagged a growing storyline: as enhanced Affordable Care Act subsidies expire and insurers exit the marketplaces, more Americans go uninsured, delay care, and then "crash into the ED," leaving struggling hospitals with unpaid bills.

5. Patients are bringing AI to the doctor's office. Both Health:Further and the payer podcasts noted patients increasingly running their own lab results through ChatGPT, the successor to "Dr. Google," whether doctors like it or not.

6. Deals & M&A Tracker

Also reported on BioSpace: Merck's anti-TL1A drug tulisokibart (centerpiece of its ~$11 billion Prometheus buyout) posted a mid-stage win in a skin condition but failed in a lung-disease study.

7. Regulatory Watch

Approvals & decisions:

• Replimune's RP1 (Tudrykev), approved for advanced melanoma after two prior rejections; priced at $450,000, an oncolytic-virus therapy for patients with few options (Biotech Hangout, BioSpace).
• Capricor's Deramiocel (Duchenne muscular dystrophy), advisory panel voted against; PDUFA decision due Aug 22.
• Orforglipron (Foundayo), the UK's MHRA became the first regulator in Europe to authorize Lilly's oral GLP-1 pill for weight management and type 2 diabetes (UK government announcement, Aug 10).

The retatrutide fight to watch: On its earnings call, Lilly "doubled down" that it will submit retatrutide as a biologic in Q1, arguing it qualifies on both amino-acid-count and "analogous-to-a-protein" grounds, a classification the FDA and courts have so far rejected (On The Pen, Aug 7). Why it matters, per the podcast: "There's no bigger story… because it would have ripple effects for every single GLP-1 that comes down the pipeline." The first appeal hearing is set for Sept 24 in Chicago. Separately, Lilly filed six new lawsuits against black-market retatrutide sellers and has referred 200+ entities to authorities.

Policy, squeezing hospitals:

• 340B drug payments cut from average-sale-price +6% to −33.4% under the new outpatient rule, "budget neutral" on paper, but Banner Health's Andy Wegman warned of "a significant impact," and questioned whether the survey behind it (only ~40% of hospitals responded) is even statistically valid (Achieving Health).
• Medicaid work requirements take effect in all expansion states Jan 1, 2027 (from the One Big Beautiful Bill Act). 25 states plus DC are suing over a new rule narrowing who counts as "medically frail." CareTalk stressed the evidence from Arkansas and Georgia: the requirements "don't actually meaningfully increase employment" but do increase disenrollment through paperwork errors, the Congressional Budget Office projects ~5.3 million losing coverage.
• Drug pricing: the first Medicare "Maximum Fair Prices" took effect in 2026, cutting selected drug prices 38–79% versus 2023 levels (~$6 billion in annual savings, per reporting).
• Hospital pay: Medicare finalized a 2.3% inpatient pay raise for 2027, which hospitals called inadequate (Health:Further).

PDUFA / decision calendar (from this week's reporting): Merck's MK-6240 Alzheimer's imaging agent (Aug 13); BMS's iberdomide for multiple myeloma (Aug 17); Merck's Keytruda + Padcev in bladder cancer (Aug 17); Eisai/Biogen's subcutaneous Leqembi (Aug 24); public comment closes Aug 24 on the FDA's proposed "Qualified Research Institutions" pilot.

8. The Week Ahead

• Aug 22: FDA decision on Capricor's Deramiocel (Duchenne), coming off a negative advisory vote, so a high-stakes call.
• Aug 24: Decision on Eisai/Biogen's subcutaneous Leqembi starting dose; also the comment deadline on the FDA's first-in-human review pilot.
• Sept 24: Lilly's retatrutide biologic-classification appeal in Chicago, the ruling that could reshape how every future GLP-1 is regulated.
• Next earnings cycle: Watch whether Lilly's Fondeo pill sales climb from that soft $98 million start, and whether retatrutide's filing lands as planned.
• Big biotech readouts: Moderna and BioNTech both have make-or-break melanoma cancer-vaccine data coming in the second half; BioNTech also has late-stage breast- and lung-cancer readouts.
• The merger question: any confirmation, or denial, on AstraZeneca–Bristol-Myers. As several hosts noted, if it happens, expect a fresh wave of pharma consolidation to follow.